Literature DB >> 8050525

The effects of antimalarials on the Plasmodium falciparum dihydroorotate dehydrogenase.

I Ittarat1, W Asawamahasakda, S R Meshnick.   

Abstract

Dihydroorotate dehydrogenase (DHOD) is a key enzyme in de novo pyrimidine biosynthesis and the major source of electrons for the mitochondrial electron transport chain of intraerythrocytic malaria parasites. DHOD and the electron transport chain may also be the site of inhibition by certain antimalarial drugs. In order to test this, Plasmodium falciparum-infected erythrocytes were exposed in vitro to artemisinin or various 8-aminoquinolines, such as primaquine, WR 238605, WR 225448, and WR 255956, and then assayed for both enzyme activity and [3H]hypoxanthine incorporation, which is an indicator of viability. Atovaquone inhibits DHOD activity to a much greater extent than hypoxanthine incorporation, which is consistent with previous reports that it targets the parasite respiratory chain. However, artemisinin and the 8-aminoquinolines inhibit DHOD to the same or lesser extent than hypoxanthine incorporation, suggesting that these compounds have different modes of action.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8050525     DOI: 10.1006/expr.1994.1058

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  14 in total

Review 1.  Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.

Authors:  Margaret A Phillips; Pradipsinh K Rathod
Journal:  Infect Disord Drug Targets       Date:  2010-06

2.  An additional mechanism of ribosome-inactivating protein cytotoxicity: degradation of extrachromosomal DNA.

Authors:  E Nicolas; I D Goodyer; T F Taraschi
Journal:  Biochem J       Date:  1997-10-15       Impact factor: 3.857

3.  8-Aminoquinolines active against blood stage Plasmodium falciparum in vitro inhibit hematin polymerization.

Authors:  J L Vennerstrom; E O Nuzum; R E Miller; A Dorn; L Gerena; P A Dande; W Y Ellis; R G Ridley; W K Milhous
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

4.  Alternative oxidase inhibitors potentiate the activity of atovaquone against Plasmodium falciparum.

Authors:  A D Murphy; N Lang-Unnasch
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

Review 5.  Antimalarial drug discovery - approaches and progress towards new medicines.

Authors:  Erika L Flannery; Arnab K Chatterjee; Elizabeth A Winzeler
Journal:  Nat Rev Microbiol       Date:  2013-11-11       Impact factor: 60.633

6.  Frequency of drug resistance in Plasmodium falciparum: a nonsynergistic combination of 5-fluoroorotate and atovaquone suppresses in vitro resistance.

Authors:  S Gassis; P K Rathod
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

Review 7.  Malaria gametocytogenesis.

Authors:  David A Baker
Journal:  Mol Biochem Parasitol       Date:  2010-04-08       Impact factor: 1.759

8.  Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase.

Authors:  I Ittarat; W Asawamahasakda; M S Bartlett; J W Smith; S R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

9.  The antileishmanial agent licochalcone A interferes with the function of parasite mitochondria.

Authors:  L Zhai; J Blom; M Chen; S B Christensen; A Kharazmi
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

Review 10.  Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections.

Authors:  C M Spencer; K L Goa
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.